<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037552</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0664</org_study_id>
    <nct_id>NCT05037552</nct_id>
  </id_info>
  <brief_title>Benefit of Hemostatic Sealant in Preservation of Ovarian Reserve</brief_title>
  <acronym>FLOKIP</acronym>
  <official_title>Additional Benefit of Hemostatic Sealant in Preservation of Ovarian Reserve During Laparoscopic Ovarian Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction : The most common technique used for ovarian cystectomy is the stripping&#xD;
      technique. After stripping the cyst wall, the subsequent bleeding of the ovarian stromal&#xD;
      wound is usually controlled by bipolar coagulation or/and by suturing. However, hemostasis&#xD;
      achieved with bipolar coagulation could result in damage to the ovarian reserve. To avoid&#xD;
      damage to healthy ovarian tissue, hemostasis using various topical hemostatic agents has been&#xD;
      introduced to control post- cystectomy ovarian wound bleeding. Among these, FloSeal (Baxter&#xD;
      Healthcare Corporation, Deer- field, IL, USA) is a hemostatic sealant composed of a&#xD;
      gelatin-based matrix and thrombin solution.&#xD;
&#xD;
      Aim: The aim of the study is to evaluate the impact of topical hemostatic sealants and&#xD;
      bipolar coagulation during laparoscopic ovarian benign cyst resection on ovarian reserve by&#xD;
      comparing the rates of decrease in anti- Müllerian hormone (AMH).&#xD;
&#xD;
      Methods: A randomized prospective data collection was made on women aged 18-45 years who&#xD;
      planned to have laparoscopic ovarian cystectomy at one of two institutions (n = 80),&#xD;
      Montpellier University Hospital and Nimes University Hospital, France. Patients were randomly&#xD;
      divided into two groups treated with either a topical hemostatic sealant (Floseal) or bipolar&#xD;
      coagulation for hemostasis. Preoperative, 3-month and 6-month postoperative AMH levels were&#xD;
      checked and the rates of decrease of AMH were compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum anti-Mullerian hormone (AMH) level preoperative</measure>
    <time_frame>Between 2 and 17 days before cystectomy</time_frame>
    <description>A biological assessment with determination of the serum AMH level will be carried out for each patient during the preoperative consultation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum anti-Mullerian hormone (AMH) level at 3 months</measure>
    <time_frame>3 months after the cystectomy</time_frame>
    <description>A biological assessment with determination of the serum AMH level will be carried out for each patient, 3 months postoperatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum anti-Mullerian hormone (AMH) level at 6 months</measure>
    <time_frame>6 months after the cystectomy</time_frame>
    <description>A biological assessment with determination of the serum AMH level will be carried out for each patient, 6 months postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to achieve hemostasis</measure>
    <time_frame>From the end of the cystectomy to the end of hemostasis (up to 1 hour)</time_frame>
    <description>The time is measured in minutes from the end of the cystectomy to the end of hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of additional hemostatsis technique</measure>
    <time_frame>From the end of the cystectomy to the end of hemostasis, during surgery</time_frame>
    <description>Another technique can be used to achieve hemostasis: bipolar forceps, suture or second hemostasis agent. The other technique will be specified if it is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>From the start of the surgery to the end of hemostasis</time_frame>
    <description>Blood loss will be measured in ml throughout the surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative adverse effects</measure>
    <time_frame>From the end of the cystectomy to the end of hemostasis</time_frame>
    <description>Adverse effects related to the coagulation procedure will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision surgery for bleeding at the operative site</measure>
    <time_frame>From the end of the cystectomy to the end of hemostasis</time_frame>
    <description>In the event of bleeding at the operative site, revision surgery may be necessary. In this case the information will be collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Benign Ovarian Cyst</condition>
  <condition>Cystectomy</condition>
  <arm_group>
    <arm_group_label>BIPOLAR FORCEPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The bipolar forceps allow electrocoagulation and are part of the standard laparoscopy box, delivered by the sterilization service to the gynecology operating room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLOSEAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLOSEAL® is a hemostatic agent based on gelatin of bovine origin added to thrombin of human origin. It is a recommended medical device in surgical procedures as an adjunct to hemostasis when control of bleeding, arterial jet seepage, ligation or any other conventional method proves impractical or ineffective.&#xD;
During this study, it will be used in 1st intention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bipolar coagulation</intervention_name>
    <description>Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.&#xD;
Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding.</description>
    <arm_group_label>BIPOLAR FORCEPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coagulation by FLOSEAL haemostatic agent</intervention_name>
    <description>Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.&#xD;
Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze.</description>
    <arm_group_label>FLOSEAL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cyst diameter between 3 and 10cm&#xD;
&#xD;
          -  Preoperative AMH level &gt;0,5ng/ml&#xD;
&#xD;
          -  Understanding and acceptance of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Post-menopausal status&#xD;
&#xD;
          -  Any suspicious finding of malignant ovarian disease&#xD;
&#xD;
          -  Change of contraception method leading to AMH variation&#xD;
&#xD;
          -  Allergy to bovine products found before inclusion&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient who has already participated in the protocol&#xD;
&#xD;
          -  Person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Person protected by law, under tutorship or curatorship&#xD;
&#xD;
          -  Patient participating in another interventional research on the human person in&#xD;
             progress&#xD;
&#xD;
          -  Refusal of participation after a period of reflection&#xD;
&#xD;
          -  Patient not affiliated or beneficiary of a national health insurance system&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha DURAES, MD</last_name>
    <role>Study Director</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha DURAES, MD</last_name>
    <phone>+334 67 33 65 32</phone>
    <email>m-duraes@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amélie DENOUEL, CRA</last_name>
    <phone>+334 67 33 55 72</phone>
    <email>a-denouel@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Martha DURAES, MD</last_name>
      <phone>+334.67.33.65.32</phone>
      <email>m-duraes@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Martha DURAES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauthier RATHA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucie REBEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara COMPAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle VINTEJOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire VINCNS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Renaud DE TAYRAC, MD PhD</last_name>
      <email>renaud.detayrac@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud DE TAYRAC, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie HUBERLAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.baxter.ca/sites/g/files/ebysai1431/files/2018-11/Floseal_EN_FR.pdf</url>
    <description>FLOSEAL user guide</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarien cyst</keyword>
  <keyword>Bipolar</keyword>
  <keyword>Ovarian reserve</keyword>
  <keyword>Hemostatic agent</keyword>
  <keyword>Coelioscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

